Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding.
| Autor: | Morgan C; School of Health and Social Care, Swansea University, Swansea, Wales., Jolles S; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff., Ponsford MJ; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff.; Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK., Evans K; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff., Carne E; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in allergy and clinical immunology [Curr Opin Allergy Clin Immunol] 2022 Dec 01; Vol. 22 (6), pp. 371-379. Date of Electronic Publication: 2022 Sep 27. |
| DOI: | 10.1097/ACI.0000000000000864 |
| Abstrakt: | Purpose of Review: Welsh immunodeficient patients on immunoglobulin replacement therapy (IgRT) who were considered high risk for severe coronavirus disease 2019 (COVID-19) were directed to shield. Consequently, patients receiving hospital-based intravenous immunoglobulin (IVIg) quickly transitioned to home-based self-administered subcutaneous immunoglobulin (SCIg). This evaluation aimed to assess patients' perceptions and experiences and laboratory outcomes of emergency IgRT transition during COVID-19. Recent Findings: A quick transition from in-hospital IVIg to home-based rapid push SCIg is achievable, however, patient IgRT administration preference remains key outside of emergency shielding measures. Summary: Subjective self-reported experiences ( n = 23) and objective immunoglobulin G (IgG) concentration ( n = 28) assessments were prospectively collected from patients pre/post-IgRT switch. In total, 41/55 (75%) patients transitioned from IVIg to rapid push SCIg and all completed training to self-administer subcutaneously within 24 days. Twenty-two percent ( n = 5) of patients preferred SCIg and 35% ( n = 8) wanted to return to hospital-based IVIg at 6 weeks post-transition. Mean IgG levels were similar pre vs. post-SCIg switch (10.3 g/l vs. 10.6 g/l, respectively). Patients reported greater infection anxiety during COVID-19 and adapted behaviours to mitigate risk. Although a third of patients wished to return to IVIg following cessation of shielding, over time the percentage electing to remain on SCIg rose from 22% to 59%. (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|